Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

14.35 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	273
Open	14.35
Bid (Size)	13.46 (100)
Ask (Size)	14.80 (200)
Prev. Close	14.35
Today's Range	14.35 - 14.35
52wk Range	12.12 - 35.34
Shares Outstanding	41,833,315
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 26, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

February 17, 2026

From Janux Therapeutics

Via Business Wire

Performance

YTD	+5.1%	+5.1%
1 Month	+2.6%	+2.6%
3 Month	-16.1%	-16.1%
6 Month	-37.7%	-37.7%
1 Year	-52.2%	-52.2%

More News

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

January 26, 2026

From Janux Therapeutics

Via Business Wire

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗

January 22, 2026

Via Stocktwits

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

January 22, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

December 23, 2025

From Janux Therapeutics

Via Business Wire

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗

December 04, 2025

Via The Motley Fool

Which stocks are moving on Tuesday? ↗

December 02, 2025

Via Chartmill

Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗

December 02, 2025

Via Chartmill

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗

December 02, 2025

Via Stocktwits

Which stocks are gapping on Tuesday? ↗

December 02, 2025

Via Chartmill

Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗

December 02, 2025

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

December 02, 2025

Via Chartmill

What's going on in today's after hours session ↗

December 01, 2025

Via Chartmill

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

December 01, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

November 24, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Janux Therapeutics

Via Business Wire

Janux (JANX) R&D Soars Revenue Misses ↗

August 07, 2025

Via The Motley Fool

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

August 07, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

August 05, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

July 24, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

July 17, 2025

From Janux Therapeutics

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2025

Via Benzinga

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 11, 2025

Via Benzinga

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 15, 2025

From Janux Therapeutics

Via Business Wire

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?

Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Janux Therapeutics, Inc. - Common Stock trade on?

Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?

The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market

What is the current price of Janux Therapeutics, Inc. - Common Stock?

The current price of Janux Therapeutics, Inc. - Common Stock is 14.35

When was Janux Therapeutics, Inc. - Common Stock last traded?

The last trade of Janux Therapeutics, Inc. - Common Stock was at 03/04/26 04:00 PM ET

What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?

The market capitalization of Janux Therapeutics, Inc. - Common Stock is 600.31M

How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?

Janux Therapeutics, Inc. - Common Stock has 600M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.